Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs by CNBC Markets | February 11, 2026 10:19 pm | US Markets Doustdar said Medicare coverage and the launch of Novo’s new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.
